Pulmonary · PANCE / PANRE

Pulmonary Hypertension

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Mean pulmonary artery pressure >20 mmHg at rest; 5 WHO groups by etiology.

Also known as: pulmonary hypertension, PH, PAH, pulmonary arterial hypertension, cor pulmonale

Overview

Resting mean pulmonary artery pressure (mPAP) >20 mmHg measured by right heart catheterization (lowered from the prior >25 mmHg threshold by the 2018 World Symposium). Classified into 5 WHO groups by mechanism.

Epidemiology

PAH (Group 1) is rare: ~15-50 cases per million. Idiopathic PAH is most common in women aged 30-50. Group 2 (left heart disease) and Group 3 (lung disease) account for the vast majority of all pulmonary hypertension cases.

Try two board-style Pulmonary Hypertension questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1PulmonaryMedium
A 65-year-old man who smokes and has chronic obstructive pulmonary disease (COPD) presents with jugular venous distention (JVD), hepatomegaly, bilateral pitting edema, a loud P2, and SpO₂ 86% at rest. Echocardiography shows right ventricular (RV) dilation with normal left ventricular (LV) function. Which of the following is the most likely diagnosis?
  • ARight ventricular infarction
  • BRestrictive cardiomyopathy
  • CCardiac tamponade
  • DCor pulmonale
Reveal answer & full explanation
Correct answer: D — Cor pulmonale
  • ARight ventricular infarction
  • BRestrictive cardiomyopathy
  • CCardiac tamponade
  • DCor pulmonale✓

Why Cor pulmonale is correct

  • Cor pulmonale is right heart failure caused by pulmonary disease; COPD is the most common cause
  • Mechanism: COPD → hypoxic pulmonary vasoconstriction → pulmonary hypertension → RV failure
  • The right-sided congestion (JVD, hepatomegaly, edema), loud P2, resting hypoxemia, and echo showing RV dilation with preserved LV function fit this diagnosis

Why the others are wrong

  • Right ventricular infarction — an acute RV infarct also gives JVD and a dilated RV, but it presents abruptly with ischemic chest pain and hypotension plus inferior ST elevation, not with chronic hepatomegaly, dependent edema, a loud P2, and resting hypoxemia (confused-with-X)
  • Cardiac tamponade — There is no effusion, pulsus paradoxus, or equalized pressures to suggest tamponade (buzzword-matching 'JVD' without the rest of the triad)
  • Restrictive cardiomyopathy — Restrictive cardiomyopathy impairs filling of both ventricles rather than producing isolated RV dilation with a clear pulmonary cause (confused-with-X)

Additional high-yield points

  • Treatment: (1) supplemental O₂ to maintain SpO₂ >90% — the only therapy proven to improve survival in COPD with resting hypoxemia; (2) optimize COPD therapy; (3) diuretics for volume overload
Question 2PulmonaryMedium
A 45-year-old male has a 3-year history of progressive dyspnea on exertion and lower extremity edema. He has no cardiac history, no anorexigen use, and a negative connective-tissue disease and HIV workup. Echo shows right ventricular enlargement with D-shaped septum, estimated right ventricular systolic pressure (RVSP) 68 mmHg, and normal left-sided pressures. Right heart catheterization: mean pulmonary artery pressure (mPAP) 42 mmHg, pulmonary capillary wedge pressure (PCWP) 9 mmHg, pulmonary vascular resistance (PVR) 8 Wood units, cardiac index (CI) 1.9 L/min/m². Ventilation-perfusion (V/Q) scan is normal. Vasodilator testing shows no response to inhaled nitric oxide. Which of the following is the most likely diagnosis?
  • ACOPD with cor pulmonale
  • BPortopulmonary hypertension
  • CIdiopathic pulmonary arterial hypertension
  • DChronic thromboembolic pulmonary hypertension
Reveal answer & full explanation
Correct answer: C — Idiopathic pulmonary arterial hypertension
  • ACOPD with cor pulmonale
  • BPortopulmonary hypertension
  • CIdiopathic pulmonary arterial hypertension✓
  • DChronic thromboembolic pulmonary hypertension

Why Idiopathic pulmonary arterial hypertension is correct

  • Idiopathic pulmonary arterial hypertension (PAH) (Group 1) is a diagnosis of exclusion, and every secondary cause here has been ruled out
  • Right heart catheterization (RHC) confirms precapillary pulmonary hypertension (PH): mean pulmonary artery pressure (mPAP) 42 mmHg (above 20 mmHg), pulmonary vascular resistance (PVR) 8 Wood units (above 2 Wood units), and pulmonary capillary wedge pressure (PCWP) 9 mmHg (below 15 mmHg)
  • Normal ventilation-perfusion (V/Q) scan excludes chronic thromboembolic disease, and a negative connective-tissue, HIV, and anorexigen history excludes associated (Group 1 secondary) causes
  • Vasodilator testing with inhaled nitric oxide showed no response, ruling out calcium channel blocker candidacy
  • Low cardiac index (CI) of 1.9 L/min/m² indicates high-risk PAH

Why the others are wrong

  • COPD with cor pulmonale — no history of obstructive lung disease; COPD-related PH typically causes only mild-to-moderate mPAP elevation, not 42 mmHg (right-concept-wrong-setting)
  • Portopulmonary hypertension — this Group 1 subtype requires underlying portal hypertension or chronic liver disease, and no cirrhosis, ascites, or varices are described (right-concept-wrong-etiology)
  • Chronic thromboembolic pulmonary hypertension — the normal V/Q scan and absent thromboembolic history exclude organized clot, which is the screening test that must be negative before calling PAH idiopathic (anchoring on precapillary PH without excluding CTEPH)

Additional high-yield points

  • Positive vasodilator response is defined as an mPAP fall above 10 mmHg to below 40 mmHg with improved cardiac output (CO) — those responders may use calcium channel blockers
  • WHO functional class guides treatment intensity
  • Initial combination therapy: the AMBITION trial showed ambrisentan plus tadalafil superior to monotherapy in WHO functional class (FC) II–III patients
  • High-risk PAH: add IV or SC prostacyclin (epoprostenol or treprostinil)
  • Balloon atrial septostomy is palliative for severe refractory PAH
  • Lung transplant is reserved for patients failing maximal medical therapy
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Pulmonary Hypertension outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • Group 1 (PAH): idiopathic, heritable (BMPR2 mutation), connective tissue disease (scleroderma, SLE), HIV, portal hypertension, congenital heart disease, drugs (methamphetamine, anorexigens, dasatinib)
  • Group 2: left-sided heart disease (HFpEF, HFrEF, valvular)
  • Group 3: chronic lung disease (COPD, IPF, OSA, hypoventilation), high altitude
  • Group 4: chronic thromboembolic pulmonary hypertension (CTEPH) — prior PE
  • Group 5: multifactorial (sarcoid, sickle cell, hemolytic anemia, ESRD, glycogen storage)

Pathophysiology

Sustained elevation of pulmonary vascular resistance causes RV pressure overload, RV hypertrophy and dilation, tricuspid regurgitation, and eventually RV failure. In PAH, pathologic vascular remodeling (intimal hyperplasia, medial hypertrophy, plexiform lesions) and dysregulated nitric oxide/endothelin/prostacyclin pathways drive disease.

Clinical presentation

Symptoms

  • Progressive exertional dyspnea (most common, often misattributed to deconditioning early)
  • Fatigue, exercise intolerance
  • Exertional chest pain, presyncope/syncope (severe disease, RV ischemia)
  • Palpitations, hemoptysis (rare)
  • Symptoms of right heart failure: lower-extremity edema, ascites, abdominal fullness

Signs / physical exam

  • Loud P2 (palpable in severe), wide split S2, RV heave/lift
  • Right-sided S3 or S4
  • Tricuspid regurgitation murmur (holosystolic at LLSB, increases with inspiration — Carvallo sign)
  • Pulmonic regurgitation murmur (Graham Steell, diastolic decrescendo)
  • Elevated JVP, hepatomegaly, ascites, peripheral edema, pulsatile liver

Classic findings

Loud P2 + RV heave + signs of right HF + clear lungs (or findings of underlying lung disease) in a dyspneic patient.

Differential diagnosis

  • Left heart failure (HFpEF or HFrEF) — Elevated PCWP (>15 mmHg) on RHC — defines post-capillary PH (Group 2); orthopnea, edema, S3
  • Chronic obstructive pulmonary disease — Obstructive spirometry, hyperinflation; mild PH common but rarely severe
  • Interstitial lung disease / IPF — Restrictive PFTs, reduced DLCO, fibrosis on HRCT
  • Obstructive sleep apnea — Witnessed apneas, daytime sleepiness, BMI elevated; polysomnography
  • CTEPH — History of PE, mismatched V/Q defects (sensitive screen); pulmonary endarterectomy may cure
  • High-output state (anemia, thyrotoxicosis, AV fistula) — Warm extremities, wide pulse pressure; reversible cause
  • Pulmonary veno-occlusive disease — PAH features with pulmonary edema after vasodilator challenge; centrilobular ground-glass on HRCT

Diagnostic workup

Diagnostic criteria

mPAP >20 mmHg on right heart cath. PAH (Group 1) additionally requires PCWP ≤15 mmHg and PVR >2 Wood units. Vasoreactivity: ≥10 mmHg decrease in mPAP to ≤40 mmHg with maintained cardiac output.

Labs

  • BNP/NT-proBNP — elevated, prognostic
  • HIV serology, hepatitis serologies (portopulmonary)
  • Connective tissue disease workup: ANA, anti-centromere, anti-Scl-70, RF, anti-CCP if indicated
  • Thrombophilia testing if CTEPH suspected
  • TSH

Imaging

  • Echocardiography (TTE) — screening modality: estimated RV systolic pressure from TR jet, RV size/function, signs of pressure overload
  • CXR — enlarged central pulmonary arteries with peripheral pruning, cardiomegaly
  • ECG — RV hypertrophy (R>S in V1), right axis deviation, P pulmonale (tall P in II), RBBB
  • V/Q scan — mandatory to exclude CTEPH (sensitivity > CTPA)
  • HRCT chest — evaluate for ILD; pulmonary CTA if PE/CTEPH suspected
  • PFTs including DLCO (low DLCO with otherwise normal PFTs suggests vasculopathy)
  • Polysomnography if OSA suspected

Other studies

  • Right heart catheterization (REQUIRED for confirmation of PAH and treatment decisions): mPAP >20 mmHg + PCWP ≤15 mmHg + PVR >2 Wood units defines pre-capillary PH; vasoreactivity testing with inhaled nitric oxide
  • 6-minute walk distance — functional assessment, prognostic

Diagnostic algorithm

WHO GroupMechanismExamples
1: PAHPulmonary arteriolar diseaseIdiopathic, heritable, CTD (scleroderma), HIV, portopulmonary, drug-induced
2: Left heart diseasePost-capillary, elevated PCWPHFpEF, HFrEF, valvular
3: Lung disease/hypoxiaChronic hypoxic vasoconstrictionCOPD, IPF, OSA, high altitude
4: CTEPHChronic thromboembolic obstructionUnresolved PE
5: MultifactorialMixed mechanismsSarcoid, sickle cell, ESRD, hematologic disorders
WHO classification of pulmonary hypertension (5 groups) — guides workup and treatment.

Treatment

First-line

  • Treat the underlying cause first: heart failure (Group 2), chronic lung disease (Group 3), CTEPH (Group 4), connective tissue or other (Group 5)
  • PAH-specific therapies are reserved for Group 1 and CTEPH inoperable patients — they can WORSEN Groups 2 and 3
  • Group 1 PAH general measures: supplemental O2 if hypoxemic, diuretics for RV volume overload, anticoagulation (idiopathic PAH only; controversial), avoid pregnancy
  • Vasoreactive responders (rare, ~10%): high-dose calcium channel blockers — nifedipine, diltiazem, amlodipine
  • Non-vasoreactive (most): combination therapy from 3 pathways:
  • Endothelin receptor antagonist (ERA): bosentan, ambrisentan, macitentan
  • Phosphodiesterase-5 inhibitor (PDE5i): sildenafil, tadalafil — OR soluble guanylate cyclase stimulator: riociguat (also approved for CTEPH)
  • Prostacyclin pathway: epoprostenol (continuous IV), treprostinil (IV/SC/inhaled/oral), iloprost (inhaled), selexipag (oral)

Second-line / adjunct

  • Severe/high-risk PAH (AMBITION trial): initial combination ambrisentan + tadalafil
  • Activin signaling inhibitor sotatercept (STELLAR 2023) — added benefit on top of background therapy
  • CTEPH (Group 4): pulmonary endarterectomy (potentially curative) for surgical candidates; riociguat for inoperable; balloon pulmonary angioplasty in select centers
  • Refractory PAH: lung or heart-lung transplantation, atrial septostomy as bridge
  • Group 3 PH from lung disease: inhaled treprostinil approved (INCREASE trial) for PH-ILD; otherwise treat underlying disease and optimize oxygen

Complications

  • Right ventricular failure, cardiogenic shock
  • Arrhythmias (atrial flutter/fibrillation poorly tolerated)
  • Hemoptysis from dilated bronchial arteries
  • Sudden cardiac death
  • Maternal mortality 30-50% in PAH — pregnancy contraindicated

PANCE pearls

  • Treatment of Group 1 PAH with PAH-specific drugs can WORSEN Groups 2 (left heart) and 3 (lung disease) — always classify before treating.
  • V/Q scan, not CTPA, is the screening test for CTEPH — sensitivity for chronic emboli is higher.
  • Right heart catheterization is required to confirm PAH and guide therapy; echo estimates can over- or underestimate by 20 mmHg.
  • Pregnancy in PAH carries ~30-50% maternal mortality — discuss avoidance/termination and effective contraception (no estrogen).
  • Bosentan is teratogenic and hepatotoxic — monthly LFTs and pregnancy testing required (REMS program).

References

  • ESC/ERS 2022 — 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (Humbert et al., Eur Heart J 2022)
  • AMBITION Trial — Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension (Galiè et al., NEJM 2015)
  • STELLAR Trial — Sotatercept for the Treatment of Pulmonary Arterial Hypertension (Hoeper et al., NEJM 2023)
  • INCREASE Trial — Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease (Waxman et al., NEJM 2021)

Practice Pulmonary questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Related Pulmonary diagnoses

AsthmaChronic Obstructive Pulmonary Disease (COPD)Community-Acquired Pneumonia (CAP)Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP)Aspiration Pneumonia and PneumonitisTuberculosis (Active and Latent)Pulmonary Embolism (PE)Pneumothorax (Spontaneous and Tension)Pleural EffusionAcute Respiratory Distress Syndrome (ARDS)Lung Cancer (Small Cell and Non-Small Cell)BronchiectasisCystic FibrosisSarcoidosis

Differentials & related conditions

Obstructive Sleep Apnea (OSA)

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.